Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R)-Nitrendipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F known ✓ | O60840 | 9/20 | 0.91 |
| ▸ | CACNA1D known ✓ | Q01668 | 9/20 | 0.91 |
| ▸ | CACNA1S known ✓ | Q13698 | 9/20 | 0.91 |
| ▸ | CACNA1C known ✓ | Q13936 | 9/20 | 0.91 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitrendipine SCHEMBL29465067 | 1.00 | HIF1A (1.00) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL15516493 | 1.00 | HIF1A (1.00) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL38972 | 1.00 | HIF1A (1.00) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| (R)-Nitrendipine SCHEMBL30228952 | 1.00 | HIF1A (1.00) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| (S)-Nitrendipine SCHEMBL120983 | 1.00 | HIF1A (1.00) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL28250729 | 0.99 | HIF1A (0.98) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL27589897 | 0.99 | HIF1A (0.98) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL10914240 | 0.99 | HIF1A (0.98) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL28360428 | 0.99 | HIF1A (0.98) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL23647366 | 0.96 | HIF1A (0.92) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18987 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107071-A1 | COMBINATION THERAPY | Retension Pharmaceuticals, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4683634-A1 | TREATMENT OF SCLERODERMA | Aisa Pharma, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4648769-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2025-11-19 | — | — | EP | claimed |
| US-20250345332-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-13 | — | — | US | claimed |
| US-12440603-B2 | Nerve grafts and methods of preparation thereof | AXOGEN CORPORATION (US) | 2025-10-14 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250281447-A1 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | ANAVEX LIFE SCIENCES CORP. | 2025-09-11 | — | — | US | claimed |
| EP-0175269-A2 | Immunogen conjugates and the use thereof in a dihydropyridine assay | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1986-03-26 | — | — | EP | claimed |
| EP-0169470-A2 | Mixture, manufacturing process and application as a drug | BAYER AG (DE) | 1986-01-29 | — | — | EP | claimed |
| EP-0167909-A2 | Solid pharmaceutical preparations containing dihydropyridine, and process for their manufacture | BAYER AG (DE) | 1986-01-15 | — | — | EP | claimed |
| EP-0166353-A2 | Benzofused lactams useful as antihypertensive agents and as cholecystokinin antagonists | MERCK & CO. INC. (US) | 1986-01-02 | — | — | EP | claimed |
| EP-0164588-A2 | Dihydropyridin compositions and manufacturing process | BAYER AG (DE) | 1985-12-18 | — | — | EP | claimed |
| EP-0163984-A2 | Dihydropyridin combinations and process for their manufacture | BAYER AG (DE) | 1985-12-11 | — | — | EP | claimed |
| EP-0163237-A2 | Di- and tri-peptidal renin inhibitors | MERCK & CO. INC. (US) | 1985-12-04 | — | — | EP | claimed |
| US-4520112-A | RADIOACTIVE LABELING | THE JOHNS HOPKINS UNIVERSITY (US) | 1985-05-28 | — | — | US | claimed |
| US-4504476-A | Method of administering calcium channel blocking agents | SCHWARTZ ARNOLD | 1985-03-12 | — | — | US | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |